HPV-associated cancers are a growing problem

November 02, 2010

HPV infection is associated with 5% of the global burden of cancers. Viral infection is linked with several cancers including those of the cervix, vagina, vulva, anus, head and neck, and penis. Although the link between HPV and both cervical and non-cervical cancers has been sufficiently proven, there are many unanswered questions and challenges surrounding HPV testing, HPV vaccination, and the management of HPV-associated cancers.

The aim of this conference, hosted by The Lancet Oncology, is to provide an opportunity for regional and international leaders from the oncology community to address the growing public-health issues associated with HPV and cancer and for delegates to debate the critical issues with thought leaders at the highest level.

Research reported at The Lancet conference in Amsterdam, taking place on November 12󈝹, will discuss issues related to HPV testing, screening, and vaccination, as well as management of HPV-associated cancers. For example, HPV vaccination is not recommended in pregnant women and Jorma Paavonen and Matti Lehtinen (University of Helsinki and University of Tampere, Finland) report on vaccination in relation to pregnancy outcome and congenital abnormalities in those who become pregnant whilst on vaccination programmes. They say: "Established pregnancy registries and postmarketing surveillance will provide further long-term data which is critical when millions of young women will be vaccinated against HPV". Data from a phase 4 community-based randomised vaccination effectiveness trial will also be discussed, as well as analyses from the PATRICIA and FUTURE II trials.

Other discussions will include age issues in relation to HPV-based screening and management of those with HPV infection, organisation of HPV screening programmes, biomarkers for screening and treatment of HPV-infected patients, HPV infection according to different ethnicities and as a prognostic factor, and vaccine and HPV testing in the developing world. Joel Palefsky (UCSF School of Medicine, USA) will also highlight prevention and treatment approaches for anal intraepithelial neoplasia and anal cancer, as well as the clinical implications of HPV infection in HIV-infected patients. Palefsky concludes: "HPV vaccination might be an important tool for anal cancer prevention in at-risk individuals".

Speakers at the conference will include: James A Bonner, University of Alabama at Birmingham, Birmingham, Alabama; Margaret Stanley, University of Cambridge, Cambridge, UK; Ian C Martin, National Confidential Enquiry into Patient Outcome and Death, London, UK; Cornelia L Trimble, Center for Cervical Disease, Johns Hopkins, Baltimore, USA; Nicolas Wentzensen, National Cancer Institute, USA; Peter J F Snijders, VU University Medical Center, Amsterdam; Guglielmo Ronco, Centre for Cancer Prevention, Turin, Italy; Marshall Posner, Dana-Farber Cancer Institute, Harvard Medical School, USA.
To request a media place at the conference, please contact: Fiona Watson T) +44 (0) 1451 830 129; E) fiona@afionconsulting.com

General Media Queries: Tony Kirby, Media Relations Manager, The Lancet Journals, T) +44 (0) 20 7424 4949 E) tony.kirby@lancet.com

For more information on the conference please visit: http://www.thelancetconferences.com/hpv-and-cancer/


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.